Su1784 ROSNILIMAB, A NOVEL PD-1 AGONIST MONOCLONAL ANTIBODY, REDUCES T CELL PROLIFERATION, INFLAMMATORY CYTOKINE SECRETION, AND PD-1 [HIGH] EXPRESSING CD4 AND CD8 T CELLS: RESULTS FROM A PHASE 1 HEALTHY VOLUNTEER CLINICAL TRIAL